youtube_live
Q3 2026 earnings • 8:00 AM tomorrow
See detailschevron_right
ALKS:NASDAQ
Alkermes Plc
$44.89
arrow_downward
-0.99%(-0.45) 1D
$44.89
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 2, 4:00:01 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALKS...
Open
$45.59
High
$45.94
Low
$44.48
Mkt. cap
7.53B
Avg. vol.
2.14M
Volume
2.16M
P/E ratio
116.64
52-wk high
$55.67
52-wk low
$27.00
EPS
$0.38
Beta
0.29
Shares outstanding
167.76M
No. of employees
2K
Open
$45.59
High
$45.94
Low
$44.48
Mkt. cap
7.53B
Avg. vol.
2.14M
Volume
2.16M
P/E ratio
116.64
52-wk high
$55.67
52-wk low
$27.00
EPS
$0.38
Beta
0.29
Shares outstanding
167.76M
No. of employees
2K
News stories
From web sources and news partners
Investing.com
·
10 hours ago
Alkermes set to report earnings amid orexin drug pipeline push
Benzinga
·
13 hours ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Profile
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
About Alkermes Plc
CEORichard F. Pops | Richard F. Pops
Employees2.05K
Founded1987
Headquarters-
SectorBiotechnology
Websitealkermes.com
Analyst ratings
Based on 12 analysts giving stock ratings to ALKS in the past 3 months
Buy
Buy
8
Hold
3
Sell
1
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for ALKS in the last 3 months.
Highest
Current $44.89
$83.00 (+84.90%)
Average
$58.27 (+29.81%)
Lowest
$38.00 (-15.35%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Ami Fadia Needham | Buy | Reiterated | $62.00 | +38.1% | 10/19/2026 |
David Amsellem Piper Sandler | Buy | Reiterated | $65.00 | +44.8% | 10/19/2026 |
Alex Nackenoff Truist Financial | Buy | Initiated | $55.00 | +22.5% | 10/16/2026 |
Unknown Analyst Truist Financial | Buy | Initiated | $55.00 | +22.5% | 10/16/2026 |
Jason Gerberry Bank of America Securities | Sell | Maintained | $38.00 | -15.3% | 10/09/2026 |
Leonid Timashev RBC Capital | Buy | Maintained | $56.00 | +24.7% | 10/08/2026 |
Paul Matteis Stifel Nicolaus | Buy | Reiterated | $63.00 | +40.3% | 10/05/2026 |
Andrea Newkirk Goldman Sachs | Hold | Initiated | $50.00 | +11.4% | 09/24/2026 |
Akash Tewari Jefferies | Buy | Maintained | $83.00 | +84.9% | 09/22/2026 |
Jessica Fye J.P. Morgan | Hold | Maintained | - | - | 09/21/2026 |
Luke Herrmann Robert W. Baird | Buy | Maintained | $61.00 | +35.9% | 09/22/2026 |
Graig Suvannavejh Mizuho Securities | Buy | Maintained | $65.00 | +44.8% | 09/22/2026 |
Douglas Tsao H.C. Wainwright | Hold | Maintained | $43.00 | -4.2% | 09/21/2026 |
Uy Ear Mizuho Securities | Buy | Maintained | $65.00 | +44.8% | 09/04/2026 |
Benjamin Burnett Wells Fargo | Buy | Reiterated | $65.00 | +44.8% | 07/29/2026 |
Joseph Thome TD Cowen | Buy | Maintained | $58.00 | +29.2% | 07/28/2026 |
Unknown Analyst Wells Fargo | Buy | Maintained | $44.00 | -2% | 05/13/2026 |
Ashwani Verma UBS | Buy | Maintained | $48.00 | +6.9% | 05/06/2026 |
Marc Goodman Leerink Partners | Hold | Maintained | - | - | 03/31/2026 |
Pete Stavropoulos Cantor Fitzgerald | Buy | Maintained | $43.00 | -4.2% | 03/11/2026 |
Joon Lee Truist Financial | Buy | Maintained | - | - | 02/26/2026 |
Rudy Li Wolfe Research | Buy | Initiated | $45.00 | +0.2% | 02/23/2026 |
Next call in 10:57:27
Tomorrow, 8:00 AM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $0.25
Revenue / Est. (USD)
- / 464.93M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 394.18M | 384.55M | 392.91M | 496.01M |
Cost of goods sold | 51.59M | 46.21M | 48.85M | 67.11M |
Cost of revenue | 51.59M | 46.21M | 48.85M | 67.11M |
Research and development expenses | 78.54M | 89.74M | 100.08M | 109.58M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 174.97M | 190.50M | 233.06M | 219.86M |
Operating expense | 253.51M | 280.23M | 344.81M | 352.03M |
Total operating expenses | 305.10M | 326.44M | 393.66M | 419.14M |
Operating income | 89.08M | 58.10M | -754.00K | 76.87M |
Other non operating income | -280.00K | 1.42M | -1.29M | 852.00K |
EBT including unusual items | 100.74M | 60.38M | -61.93M | -1.88M |
EBT excluding unusual items | 100.74M | 60.38M | -14.40M | 57.14M |
Income tax expense | 17.98M | 11.04M | 4.55M | -2.38M |
Effective tax rate | 17.85% | 18.28% | -7.35% | 126.71% |
Other operating expenses | - | - | - | - |
Net income | 82.76M | 49.34M | -66.48M | 501.00K |
Net profit margin | 21.00% | 12.83% | -16.92% | 0.10% |
Earnings per share | 0.65 | 0.48 | 0.38 | 0.70 |
Interest and investment income | 11.94M | 12.13M | 8.54M | 5.34M |
Interest expense | - | -12.28M | -20.89M | -25.92M |
Net interest expenses | 11.94M | -147.00K | -12.35M | -20.58M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 97.16M | 61.95M | 18.68M | 107.14M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events